Kimelman & Baird LLC Has $3.27 Million Holdings in Bristol-Myers Squibb Company (BMY)

Kimelman & Baird LLC trimmed its stake in Bristol-Myers Squibb Company (NYSE:BMY) by 13.3% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 58,748 shares of the biopharmaceutical company’s stock after selling 9,000 shares during the quarter. Kimelman & Baird LLC’s holdings in Bristol-Myers Squibb were worth $3,273,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of BMY. RNC Capital Management LLC boosted its stake in shares of Bristol-Myers Squibb by 7,267.1% during the 2nd quarter. RNC Capital Management LLC now owns 823,566 shares of the biopharmaceutical company’s stock worth $45,889,000 after acquiring an additional 812,387 shares during the period. Sentry Investment Management LLC boosted its stake in shares of Bristol-Myers Squibb by 1.0% during the 2nd quarter. Sentry Investment Management LLC now owns 132,068 shares of the biopharmaceutical company’s stock worth $7,359,000 after acquiring an additional 1,326 shares during the period. Atlantic Trust LLC bought a new position in shares of Bristol-Myers Squibb during the 2nd quarter worth approximately $111,000. WFG Advisors LP boosted its stake in shares of Bristol-Myers Squibb by 5.9% during the 2nd quarter. WFG Advisors LP now owns 23,928 shares of the biopharmaceutical company’s stock worth $1,333,000 after acquiring an additional 1,328 shares during the period. Finally, Toronto Dominion Bank boosted its stake in shares of Bristol-Myers Squibb by 23.0% during the 2nd quarter. Toronto Dominion Bank now owns 571,612 shares of the biopharmaceutical company’s stock worth $31,844,000 after acquiring an additional 107,021 shares during the period. Hedge funds and other institutional investors own 69.82% of the company’s stock.

Several brokerages have recently commented on BMY. Jefferies Group reiterated a “buy” rating and set a $72.00 target price on shares of Bristol-Myers Squibb in a research note on Wednesday, September 27th. Cowen restated a “hold” rating and issued a $65.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday, September 19th. Piper Jaffray Companies restated a “hold” rating and issued a $60.00 price target on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Vetr upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $64.08 price target for the company in a research note on Thursday, August 17th. Finally, Credit Suisse Group restated a “hold” rating on shares of Bristol-Myers Squibb in a research note on Friday, September 8th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $64.93.

In related news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the business’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total transaction of $335,172.00. Following the sale, the executive vice president now owns 9,251 shares in the company, valued at approximately $585,033.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Sandra Leung sold 156,582 shares of the business’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the sale, the executive vice president now owns 584,373 shares in the company, valued at approximately $37,031,717.01. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by insiders.

Bristol-Myers Squibb Company (NYSE BMY) opened at $62.13 on Friday. The firm has a market capitalization of $103,881.36, a price-to-earnings ratio of 21.44, a price-to-earnings-growth ratio of 2.41 and a beta of 1.18. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. Bristol-Myers Squibb Company has a fifty-two week low of $46.01 and a fifty-two week high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. During the same period last year, the firm posted $0.77 EPS. Bristol-Myers Squibb’s quarterly revenue was up 6.7% on a year-over-year basis. equities research analysts anticipate that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be issued a dividend of $0.40 per share. The ex-dividend date is Thursday, January 4th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.58%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s payout ratio is 61.42%.

TRADEMARK VIOLATION WARNING: “Kimelman & Baird LLC Has $3.27 Million Holdings in Bristol-Myers Squibb Company (BMY)” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://ledgergazette.com/2017/12/15/kimelman-baird-llc-has-3-27-million-holdings-in-bristol-myers-squibb-company-bmy-2.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply